Literature DB >> 23393207

Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Johan Pallud1, Marie Blonski, Emmanuel Mandonnet, Etienne Audureau, Denys Fontaine, Nader Sanai, Luc Bauchet, Philippe Peruzzi, Marc Frénay, Philippe Colin, Rémy Guillevin, Valérie Bernier, Marie-Hélène Baron, Jacques Guyotat, Hugues Duffau, Luc Taillandier, Laurent Capelle.   

Abstract

BACKGROUND: Supratentorial diffuse low-grade gliomas present a slow macroscopic tumor growth that can be quantified through the measurement of their velocity of diametric expansion. We assessed whether spontaneous velocity of diametric expansion can predict long-term outcomes as a categorical variable and as a continuous predictor.
METHODS: A total of 407 adult patients with newly diagnosed supratentorial diffuse low-grade gliomas in adults were studied.
RESULTS: The mean spontaneous velocity of diametric expansion before first-line treatment was 5.8 ± 6.3 mm/year. During the follow-up (mean, 86.5 ± 59.4 months), 209 patients presented a malignant transformation, and 87 died. The malignant progression-free survival and the overall survival were significantly longer in cases of slow velocity of diametric expansion (median, 103 and 249 months, respectively) than in cases of fast velocity of diametric expansion (median, 35 and 91 months, respectively; P < .001). In multivariate analyses, spontaneous velocity of diametric expansion as a categorical variable (<4, ≥4 and <8, ≥8 and <12, ≥12 mm/year) was an independent prognostic factor for malignant progression-free survival (P < .001; hazard ratio, 3.87; 95% confidence interval [CI], 2.67-5.52) and for overall survival (P < .001; hazard ratio, 4.62; 95% CI, 2.58-7.97). Velocity of diametric expansion was also an independent prognostic factor for overall survival as a continuous predictor, showing a linear relationship between overall survival and spontaneous velocity of diametric expansion (hazard ratio, 1.09 per one unit increase; 95% CI, 1.06-1.12; P < .001).
CONCLUSIONS: Independent of the molecular status, the spontaneous velocity of diametric expansion allows the identification of rapidly growing diffuse low-grade gliomas (at higher risk of worsened evolution) during the pretherapeutic period and without delaying treatment.

Entities:  

Mesh:

Year:  2013        PMID: 23393207      PMCID: PMC3635513          DOI: 10.1093/neuonc/nos331

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  27 in total

Review 1.  Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates.

Authors:  Johan Pallud; Luc Taillandier; Laurent Capelle; Denys Fontaine; Matthieu Peyre; François Ducray; Hugues Duffau; Emmanuel Mandonnet
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

2.  Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Jean-François Llitjos; Frédéric Dhermain; Pascale Varlet; Edouard Dezamis; Bertrand Devaux; Raphaëlle Souillard-Scémama; Nader Sanai; Maria Koziak; Philippe Page; Michel Schlienger; Catherine Daumas-Duport; Jean-François Meder; Catherine Oppenheim; François-Xavier Roux
Journal:  Neuro Oncol       Date:  2012-03-13       Impact factor: 12.300

3.  Comment on parameters of low-grade glioma as predictors.

Authors:  Johan Pallud; Laurent Capelle; Emmanuel Mandonnet
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

4.  Natural history of incidental World Health Organization grade II gliomas.

Authors:  Johan Pallud; Denys Fontaine; Hugues Duffau; Emmanuel Mandonnet; Nader Sanai; Luc Taillandier; Philippe Peruzzi; Rémy Guillevin; Luc Bauchet; Valérie Bernier; Marie-Hélène Baron; Jacques Guyotat; Laurent Capelle
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

Review 5.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

6.  Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology.

Authors:  Kristin R Swanson; Russell C Rockne; Jonathan Claridge; Mark A Chaplain; Ellsworth C Alvord; Alexander R A Anderson
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

7.  1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.

Authors:  Catherine Gozé; Charlotte Bezzina; Eric Gozé; Valérie Rigau; Thierry Maudelonde; Luc Bauchet; Hugues Duffau
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

8.  Continuous growth of mean tumor diameter in a subset of grade II gliomas.

Authors:  Emmanuel Mandonnet; Jean-Yves Delattre; Marie-Laure Tanguy; Kristin R Swanson; Antoine F Carpentier; Hugues Duffau; Philippe Cornu; Rémy Van Effenterre; Ellsworth C Alvord; Laurent Capelle
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

9.  Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Authors:  Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

10.  Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

Authors:  R Soffietti; B G Baumert; L Bello; A Von Deimling; H Duffau; M Frénay; W Grisold; R Grant; F Graus; K Hoang-Xuan; M Klein; B Melin; J Rees; T Siegal; A Smits; R Stupp; W Wick
Journal:  Eur J Neurol       Date:  2010-09       Impact factor: 6.089

View more
  51 in total

1.  Impact of imaging measurements on response assessment in glioblastoma clinical trials.

Authors:  David A Reardon; Karla V Ballman; Jan C Buckner; Susan M Chang; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 2.  'Low grade glioma': an update for radiologists.

Authors:  Jennifer Larsen; Steve B Wharton; Fiona McKevitt; Charles Romanowski; Caroline Bridgewater; Hesham Zaki; Nigel Hoggard
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

3.  Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Authors:  Catherine Gozé; Marie Blonski; Guillaume Le Maistre; Luc Bauchet; Edouard Dezamis; Philippe Page; Pascale Varlet; Laurent Capelle; Bertrand Devaux; Luc Taillandier; Hugues Duffau; Johan Pallud
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

Review 4.  The role of surgery in grade II/III oligodendroglial tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  CNS Oncol       Date:  2015-10-19

Review 5.  New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

Authors:  Hugues Duffau; Luc Taillandier
Journal:  Neuro Oncol       Date:  2014-08-02       Impact factor: 12.300

6.  Is a prospective trial necessary to suggest a clinical relevance?

Authors:  Johan Pallud; Hugues Duffau
Journal:  Neuro Oncol       Date:  2014-08-05       Impact factor: 12.300

7.  Is the volume of low-grade glioma measurable and is it clinically relevant?

Authors:  Marc C Chamberlain
Journal:  Neuro Oncol       Date:  2014-06-20       Impact factor: 12.300

8.  Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Authors:  C Izquierdo; A Alentorn; A Idbaih; M Simó; G Kaloshi; D Ricard; M Barritault; D Meyronet; J Bruna; J Honnorat; J Y Delattre; F Ducray
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

9.  A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.

Authors:  Sibel Isal; Guillaume Gauchotte; Fabien Rech; Marie Blonski; Sophie Planel; Mohammad B Chawki; Gilles Karcher; Pierre-Yves Marie; Luc Taillandier; Antoine Verger
Journal:  Br J Radiol       Date:  2018-01-12       Impact factor: 3.039

10.  Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.

Authors:  Alexandre Roux; Arnault Tauziede-Espariat; Marc Zanello; Sophie Peeters; Gilles Zah-Bi; Eduardo Parraga; Myriam Edjlali; Emmanuèle Lechapt; Natalia Shor; Luisa Bellu; Giulia Berzero; Didier Dormont; Edouard Dezamis; Fabrice Chretien; Catherine Oppenheim; Marc Sanson; Pascale Varlet; Laurent Capelle; Frédéric Dhermain; Johan Pallud
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.